Article
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Nature microbiology - 1 Sept 2021
Zahradník Jiří, Marciano Shir, Shemesh Maya, Zoler Eyal, Harari Daniel, Chiaravalli Jeanne, Meyer Björn, Rudich Yinon, Li Chunlin, Marton Ira, Dym Orly, Elad Nadav, Lewis Mark G, Andersen Hanne, Gagne Matthew, Seder Robert A, Douek Daniel C, Schreiber Gideon
Abstract excerpt
SARS-CoV-2 variants of interest and concern will continue to emerge for the duration of the COVID-19 pandemic. To map mutations in the receptor-binding domain (RBD) of the spike protein that affect binding to angiotensin-converting enzyme 2 (ACE2), the receptor for SARS-CoV-2, we applied in vitro evolution to affinity-mature the RBD. Multiple rounds of random mutagenic libraries of the RBD were sorted against...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.